The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Waltermire Robert E. since 2023.
This trader's CIK number is 1876996.
At the time of last reporting, Waltermire Robert E. was the Senior VP, Chief Pharma Dev. of Madrigal Pharmaceuticals, Inc.. (stock ticker symbol MDGL).
Also see all insider trading activities at Madrigal Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | MDGL | 0 | $0 | 14,658 | $4,959,737 | 14,113 | $1,234,958 |
| 2024 | MDGL | 0 | $0 | 4,936 | $1,341,668 | 3,900 | $341,311 |
| 2023 | MDGL | 0 | $0 | 17,800 | $4,521,490 | 17,800 | $1,564,976 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-05 | MDGL | Option Ex | 14,113 | 87.50 | 1,234,958 |
| 2025-03-05 | MDGL | Sale | 14,113 | 340.42 | 4,804,361 |
| 2025-01-24 | MDGL | Sale | 103 | 335.24 | 34,529 |
| 2025-01-17 | MDGL | Sale | 442 | 273.41 | 120,847 |
| 2024-06-14 | MDGL | Sale | 1,900 | 280.00 | 532,000 |
| 2024-06-14 | MDGL | Option Ex | 1,900 | 87.09 | 165,471 |
| 2024-06-12 | MDGL | Sale | 2,000 | 285.00 | 570,000 |
| 2024-06-12 | MDGL | Option Ex | 2,000 | 87.92 | 175,840 |
| 2024-05-21 | MDGL | Sale | 1,036 | 231.34 | 239,668 |
| 2023-12-14 | MDGL | Sale | 2,000 | 232.50 | 465,000 |
| 2023-12-15 | MDGL | Sale | 2,000 | 238.50 | 477,000 |
| 2023-12-14 | MDGL | Option Ex | 2,000 | 87.92 | 175,840 |
| 2023-12-15 | MDGL | Option Ex | 2,000 | 87.92 | 175,840 |
| 2023-12-13 | MDGL | Sale | 2,500 | 225.50 | 563,750 |
| 2023-12-12 | MDGL | Sale | 1,300 | 217.50 | 282,750 |
| 2023-12-13 | MDGL | Option Ex | 2,500 | 87.92 | 219,800 |
| 2023-12-12 | MDGL | Option Ex | 1,300 | 87.92 | 114,296 |
| 2023-02-28 | MDGL | Option Ex | 5,000 | 87.92 | 439,600 |
| 2023-03-01 | MDGL | Option Ex | 5,000 | 87.92 | 439,600 |
| 2023-02-28 | MDGL | Sale | 5,000 | 271.67 | 1,358,325 |
| 2023-03-01 | MDGL | Sale | 5,000 | 274.93 | 1,374,665 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Waltermire Robert E. (Senior VP, Chief Pharma Dev. of Madrigal Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.